vs
Side-by-side financial comparison of Freeport-McMoRan (FCX) and Fresenius Medical Care AG (FMS). Click either name above to swap in a different company.
Fresenius Medical Care AG is the larger business by last-quarter revenue ($5.5B vs $5.3B, roughly 1.0× Freeport-McMoRan). Freeport-McMoRan runs the higher net margin — 10.7% vs 7.9%, a 2.8% gap on every dollar of revenue. On growth, Fresenius Medical Care AG posted the faster year-over-year revenue change (-0.3% vs -10.4%).
Freeport-McMoRan Inc., often called Freeport, is an American mining company based in the Freeport-McMoRan Center, in Phoenix, Arizona. The company is the world's largest producer of molybdenum, a major copper producer and operates the world's largest gold mine, the Grasberg mine in Papua, Indonesia.
Fresenius Medical Care AG & Co. KGaA is a German healthcare company which provides kidney dialysis services through a network of 4,171 outpatient dialysis centers, serving 345,425 patients. The company primarily treats end-stage renal disease (ESRD), which requires patients to undergo dialysis 3 times per week for the rest of their lives.
FCX vs FMS — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $5.3B | $5.5B |
| Net Profit | $565.0M | $434.2M |
| Gross Margin | 12.4% | 27.4% |
| Operating Margin | 15.4% | 11.7% |
| Net Margin | 10.7% | 7.9% |
| Revenue YoY | -10.4% | -0.3% |
| Net Profit YoY | -21.6% | 240.4% |
| EPS (diluted) | — | — |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $5.3B | $5.5B | ||
| Q3 25 | $6.8B | — | ||
| Q2 25 | $7.5B | — | ||
| Q1 25 | $5.6B | — | ||
| Q4 24 | $5.9B | $5.5B | ||
| Q3 24 | $6.7B | — | ||
| Q2 24 | $6.4B | — | ||
| Q1 24 | $6.2B | — |
| Q4 25 | $565.0M | $434.2M | ||
| Q3 25 | $1.2B | — | ||
| Q2 25 | $1.5B | — | ||
| Q1 25 | $793.0M | — | ||
| Q4 24 | $721.0M | $127.6M | ||
| Q3 24 | $1.2B | — | ||
| Q2 24 | $1.3B | — | ||
| Q1 24 | $1.2B | — |
| Q4 25 | 12.4% | 27.4% | ||
| Q3 25 | 29.2% | — | ||
| Q2 25 | 34.2% | — | ||
| Q1 25 | 24.3% | — | ||
| Q4 24 | 27.0% | 25.0% | ||
| Q3 24 | 30.0% | — | ||
| Q2 24 | 31.5% | — | ||
| Q1 24 | 28.5% | — |
| Q4 25 | 15.4% | 11.7% | ||
| Q3 25 | 28.9% | — | ||
| Q2 25 | 32.3% | — | ||
| Q1 25 | 23.4% | — | ||
| Q4 24 | 21.1% | 5.1% | ||
| Q3 24 | 29.0% | — | ||
| Q2 24 | 32.0% | — | ||
| Q1 24 | 26.3% | — |
| Q4 25 | 10.7% | 7.9% | ||
| Q3 25 | 18.3% | — | ||
| Q2 25 | 20.6% | — | ||
| Q1 25 | 14.2% | — | ||
| Q4 24 | 12.3% | 2.3% | ||
| Q3 24 | 18.5% | — | ||
| Q2 24 | 20.0% | — | ||
| Q1 24 | 18.7% | — |
| Q4 25 | — | — | ||
| Q3 25 | $0.46 | — | ||
| Q2 25 | $0.53 | — | ||
| Q1 25 | $0.24 | — | ||
| Q4 24 | — | — | ||
| Q3 24 | $0.36 | — | ||
| Q2 24 | $0.42 | — | ||
| Q1 24 | $0.32 | — |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $3.8B | $1.7B |
| Total DebtLower is stronger | $9.4B | — |
| Stockholders' EquityBook value | $18.9B | $15.4B |
| Total Assets | $58.2B | $33.5B |
| Debt / EquityLower = less leverage | 0.50× | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $3.8B | $1.7B | ||
| Q3 25 | $4.3B | — | ||
| Q2 25 | $4.5B | — | ||
| Q1 25 | $4.4B | — | ||
| Q4 24 | $3.9B | $1.3B | ||
| Q3 24 | $5.0B | — | ||
| Q2 24 | $5.3B | — | ||
| Q1 24 | $5.2B | — |
| Q4 25 | $9.4B | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | $9.4B | — | ||
| Q4 24 | $8.9B | — | ||
| Q3 24 | $9.7B | — | ||
| Q2 24 | $9.4B | — | ||
| Q1 24 | $9.4B | — |
| Q4 25 | $18.9B | $15.4B | ||
| Q3 25 | $18.7B | — | ||
| Q2 25 | $18.2B | — | ||
| Q1 25 | $17.7B | — | ||
| Q4 24 | $17.6B | $17.0B | ||
| Q3 24 | $17.5B | — | ||
| Q2 24 | $17.4B | — | ||
| Q1 24 | $17.0B | — |
| Q4 25 | $58.2B | $33.5B | ||
| Q3 25 | $56.8B | — | ||
| Q2 25 | $56.5B | — | ||
| Q1 25 | $56.0B | — | ||
| Q4 24 | $54.8B | $36.3B | ||
| Q3 24 | $55.4B | — | ||
| Q2 24 | $54.6B | — | ||
| Q1 24 | $54.2B | — |
| Q4 25 | 0.50× | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | 0.53× | — | ||
| Q4 24 | 0.51× | — | ||
| Q3 24 | 0.55× | — | ||
| Q2 24 | 0.54× | — | ||
| Q1 24 | 0.56× | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $693.0M | $2.9B |
| Free Cash FlowOCF − Capex | $-312.0M | — |
| FCF MarginFCF / Revenue | -5.9% | — |
| Capex IntensityCapex / Revenue | 19.1% | — |
| Cash ConversionOCF / Net Profit | 1.23× | 6.67× |
| TTM Free Cash FlowTrailing 4 quarters | $1.1B | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $693.0M | $2.9B | ||
| Q3 25 | $1.7B | — | ||
| Q2 25 | $2.2B | — | ||
| Q1 25 | $1.1B | — | ||
| Q4 24 | $1.4B | $2.6B | ||
| Q3 24 | $1.9B | — | ||
| Q2 24 | $2.0B | — | ||
| Q1 24 | $1.9B | — |
| Q4 25 | $-312.0M | — | ||
| Q3 25 | $608.0M | — | ||
| Q2 25 | $934.0M | — | ||
| Q1 25 | $-114.0M | — | ||
| Q4 24 | $197.0M | — | ||
| Q3 24 | $673.0M | — | ||
| Q2 24 | $840.0M | — | ||
| Q1 24 | $642.0M | — |
| Q4 25 | -5.9% | — | ||
| Q3 25 | 8.9% | — | ||
| Q2 25 | 12.4% | — | ||
| Q1 25 | -2.0% | — | ||
| Q4 24 | 3.4% | — | ||
| Q3 24 | 10.1% | — | ||
| Q2 24 | 13.1% | — | ||
| Q1 24 | 10.3% | — |
| Q4 25 | 19.1% | — | ||
| Q3 25 | 15.5% | — | ||
| Q2 25 | 16.8% | — | ||
| Q1 25 | 21.0% | — | ||
| Q4 24 | 21.1% | — | ||
| Q3 24 | 17.9% | — | ||
| Q2 24 | 17.4% | — | ||
| Q1 24 | 20.2% | — |
| Q4 25 | 1.23× | 6.67× | ||
| Q3 25 | 1.33× | — | ||
| Q2 25 | 1.42× | — | ||
| Q1 25 | 1.33× | — | ||
| Q4 24 | 1.99× | 20.20× | ||
| Q3 24 | 1.51× | — | ||
| Q2 24 | 1.53× | — | ||
| Q1 24 | 1.63× | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
FCX
| Morenci | $2.5B | 47% |
| Grasberg Segment | $964.0M | 18% |
| Copper In Concentrates | $934.0M | 18% |
| Molybdenum | $541.0M | 10% |
| Gold | $388.0M | 7% |
FMS
Segment breakdown not available.
